Financial comparisons PCL, Inc.

Stocks

End-of-day quote Korea S.E. 2025-03-21			5-day change	1st Jan Change
6,040.00 ^KRW	-1.63%		-.--%	-

24-12-29	Yeom Ju-hwan agreed to acquire 36.90% stake in mCureX Therapeutics, Inc. from PCL, Inc. for KRW 13.0 billion.	CI
24-08-29	PCL, Inc. announced that it has received KRW 4.004999835 billion in funding	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Revenues (N-1)	Net Margin (N-1)	EBIT Margin (N-1)	ROE (N-1)	ROA (N-1)	Leverage (N-1)
ADAPTIVE BIOTECHNOLOGIES CORPORATION	277M	-21.48%	-20.62%	-27.84%	-11.31%	-8.26x
VERACYTE, INC.	517M	12.83%	11.17%	11.52%	-	-2.9x
IOVANCE BIOTHERAPEUTICS, INC.	264M	-148.38%	-153.08%	-55.5%	-	0.83x
CAREDX, INC.	380M	-5.62%	-8.1%	-	-	-
SEEGENE, INC.	329M	10.18%	7.29%	4.81%	3.94%	-2.66x
MARAVAI LIFESCIENCES HOLDINGS, INC.	186M	-70.41%	-44.52%	-57.13%	-14.7%	-2.4x
INSIGHT MOLECULAR DIAGNOSTICS INC.	4.06M	-1,238.52%	-1,260.76%	-	-	-
SCOPE FLUIDICS S.A.	27.83K	-46,364%	-47,282%	-30.03%	-25.14%	3.43x
APPLIED BIOCODE CORPORATION	15.13M	-42.34%	-47%	-26.44%	-18.06%	-
BATM ADVANCED COMMUNICATIONS LTD.	123M	-14.88%	11.93%	-	-	-0.78x
Average	209M	-4,788.26%	-4,878.57%	-25.8%	-13.06%	-1.82x
Weighted average by Cap.	338M	-404.55%	-411.94%	-22.89%	-9.56%	-3.58x